METHODS: A systematic search in Medline, Embase, The Cochrane Library, Web of Science, CIHNAL and PEDro was conducted in June 2023. Two reviewers independently screened abstracts according to the eligibility criteria.
RESULTS: Twenty-five articles were included in this review. Only six studies reported adverse events, all of which were considered minor. None of the included studies reported any serious adverse events. In four of the included studies anticoagulants were regarded as contra-indicative for DN. Anticoagulants were not mentioned in the other included studies.
CONCLUSIONS: There is a paucity of literature concerning the safety of DN in stroke patients. This review is the first to investigate the safety of DN in stroke patients and based on the results there is insufficient evidence regarding the safety of DN in stroke patients.
CONCLUSIONS: Although DN could be a promising treatment in post-stroke spasticity, further research is indicated to investigate its mechanism of action and its effect on outcome. However, before conducting large clinical trials to assess outcome parameters, the safety of DN in stroke patients must be further investigated.
方法:Medline中的系统搜索,Embase,科克伦图书馆,WebofScience,CIHNAL和PEDro于2023年6月进行。两名审稿人根据资格标准独立筛选摘要。
结果:本综述包括25篇文章。只有六项研究报告了不良事件,所有这些都被认为是次要的。纳入的研究均未报告任何严重不良事件。在纳入的四项研究中,抗凝剂被认为是DN的禁忌指标。在其他纳入研究中未提及抗凝剂。
结论:结论:关于DN在卒中患者中的安全性的文献很少。这篇综述是首次研究DN在卒中患者中的安全性,基于该结果,关于DN在卒中患者中的安全性的证据不足。
结论:尽管DN可能是治疗卒中后痉挛的一种有希望的治疗方法,进一步研究表明其作用机制及其对结局的影响。然而,在进行大型临床试验以评估结果参数之前,必须进一步研究DN在脑卒中患者中的安全性。